Age Dependend Diagnostic Thresholds for Osteoporosis Bindex Ultrasonometer
NCT ID: NCT01978834
Last Updated: 2015-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
560 participants
OBSERVATIONAL
2013-10-31
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
First, the thresholds for DI will be determined by measuring 70 osteoporotic and 70 healthy patients (n = 140) with Bindex and DXA within four decades of age; age 50 to 59 years, age 60 to 69 years, age 70 to 79 years, and age 80 to 89 years. The feasibility of DI for diagnostics of osteoporosis and evaluation of bone mineral density (BMD) will be assessed. The thresholds for the BMD estimate obtained with DI will be determined for osteoporotic and non-osteoporotic patients. For fracture risk assessment, DI measurements are used to predict the outcome of currently available fracture risk assessment tools.
1. To investigate optimal configuration of ultrasound parameters and patient characteristics for prediction of proximal femur and lumbar spine BMD for women in each four decades of age; 50 to 59 years, 60 to 69 years, 70 to 79 years, and 80-89 years.
2. To develop national diagnostic thresholds for DI in prediction of osteoporosis status with a reference female population (American-Caucasian) in each four decades of age; 50 to 59 years, 60 to 69 years, 70 to 79 years, and 80-89 years.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bindex Ultrasonometer for Osteoporosis Diagnostics
NCT01935232
Bindex for Osteoporosis Diagnostics
NCT03878732
Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX
NCT01998737
Develop and Validate Ultrasonic Device for Osteoporotic Fracture Risk Assessment
NCT01123421
Clinical Study to Estimate Bone Mineral Density With the POROUS Ultrasound Device
NCT07187518
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The data for determination of diagnostic threshold for DI in North American population will be analyzed by Bone Index Finland. The data will include following parameters:
* Age in years
* Weight
* Height
* Cortical thickness values at each location
* Density Index values
* Raw data on ultrasound signals.
* DXA measurement data
* Identification code (Uniquely created identification code given to a subject, does not carry any information on subject but enables tracing if needed.)
* Data from Appendix A, excluding patient name and medical record number
Risk factors will be collected in a separate questionnaire (Appendix A).
1. Name
2. Medical Record Number
3. Weight (kg)
4. Height (cm)
5. Chair Stand test Can do easily; can do only with difficulty; cannot do
Risk Factors:
6. Previous fracture (Skeletal site, age at which fracture occured)
7. Parent fractured hip (Yes, No)
8. Current smoking (Yes, No)
9. Glucocorticoid Use (Yes, No)
10. Rheumatoid arthritis (Yes, No)
11. Alcohol 3 or more units per day (Yes, No)
12. Osteoporosis medication, type (e.g. alendronate, bisphosphonates), start- and end-date (Within the past five years)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 50 to 89 years
Exclusion Criteria
* Inability to sign consent form due to cognitive impairment. Those with dementia (ICD-9 diagnosis codes 331.0, 294.1, 294.10, 294.11, or 294.8) will excluded from mailed recruitment
* Measurement of hip BMD is not feasible (for example, those who have had bilateral hip replacement surgeries or who cannot have central DXA because of their body weight)
* Open leg or arm wounds at sites where ultrasound measurements are supposed to be taken, precluding such measurements
50 Years
89 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HealthPartners Institute
OTHER
Bone Index Finland Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John T Schousboe, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
HealthPartners Institute
Janne P Karjalainen, PhD
Role: STUDY_DIRECTOR
Bone Index Finland Ltd
Ossi Riekkinen, PhD
Role: STUDY_DIRECTOR
Bone Index Finland Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Park Nicollet Institute
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BoneIndex02
Identifier Type: OTHER
Identifier Source: secondary_id
Bind02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.